GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Insight Molecular Diagnostics
The value of Insight Molecular Diagnostics, like any company in the molecular diagnostics field, is determined by the accuracy of its tests and its ability to obtain regulatory approval. The potential share price will depend on the implementation of its technologies in clinical practice.
Share prices of companies in the market segment - Medanalysis
IMDX (a shell company) was created to merge with another company. Its target sector is medical diagnostics. We'll categorize it as "Medanalysis," and the chart below shows how investors view the prospects of this industry, which has become particularly relevant in recent years.
Broad Market Index - GURU.Markets
Insight Molecular is a company developing and commercializing diagnostic tests for disease detection and monitoring. As a participant in this sector, it is included in our GURU.Markets index. The chart below reflects the overall stock market performance. Compare it with the company's stock price to assess the industry's prospects.
Change in the price of a company, segment, and market as a whole per day
IMDX - Daily change in the company's share price Insight Molecular Diagnostics
For Insight Molecular Diagnostics, daily price volatility reflects its sensitivity to news about the development and approval of new diagnostic tests. This metric is an important component in formulas that assess the risks and potential of companies in the medical diagnostics sector.
Daily change in the price of a set of shares in a market segment - Medanalysis
Insight Molecular Diagnostics is a medical diagnostics company. This chart shows the sector's high volatility. Comparing it to IMDX's performance, which depends on the approval of new tests, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Insight Molecular Diagnostics is a biotechnology company operating in the field of medical diagnostics. Its shares represent a venture bet on scientific success and the commercialization of new tests. Their high volatility contributes to the complex and multifaceted dynamics of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Insight Molecular Diagnostics
Insight Molecular Diagnostics' year-to-date performance is a story about the development and commercialization of its diagnostic tests. Its 12-month market cap depends on progress in clinical trials, regulatory approvals, and partnerships with major laboratories, where it must prove the accuracy and clinical utility of its tests.
Annual dynamics of market capitalization of the market segment - Medanalysis
Insight, as a private diagnostics company, likely specializes in advanced molecular tests. Its growth depends on scientific breakthroughs and securing insurance coverage. Its valuation is likely outperforming the sector due to its innovation, but carries higher risks associated with R&D.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Insight Molecular Diagnostics appears to be privately held or defunct. The IMDX ticker is inactive, making it impossible to analyze its market performance. If such a company existed, its diagnostics business would be defensive, and its stock performance would be driven by scientific advances, not economics.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Insight Molecular Diagnostics
Insight Molecular Diagnostics is a molecular diagnostics company. Its value is based on the potential of its technologies. Monthly fluctuations reflect progress in test development and validation, as well as news of regulatory approvals or laboratory partnerships.
Monthly dynamics of market capitalization of the market segment - Medanalysis
Insight Molecular Diagnostics is a company operating in the field of medical analytics and diagnostics. Its sector dynamics, shown in the chart, reflect its investments in healthcare and scientific breakthroughs. Against this backdrop, one can assess how the company's innovative diagnostic solutions position it in the rapidly developing personalized medicine market.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Insight Molecular Diagnostics, like any company in the medical diagnostics sector, depends on the success of developing and commercializing its tests. Its shares are weakly correlated with the market. The chart will show performance driven by internal events, such as regulatory approvals or scientific publications, rather than by overall economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Insight Molecular Diagnostics
Insight Molecular Diagnostics, a medical diagnostics company, whose weekly stock performance reflects innovations in assays and testing. News about the development of new diagnostic platforms, partnerships, and regulatory approvals drives highly volatile short-term trends.
Weekly dynamics of market capitalization of the market segment - Medanalysis
Insight Molecular Diagnostics, as its name suggests, operates in the field of molecular diagnostics. This cutting-edge medical sector relies on innovation and regulatory approvals. The chart allows you to compare its weekly performance with the sector and understand whether fluctuations reflect general trends or unique company news.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Insight Molecular Diagnostics is a company operating in the molecular diagnostics field. Its shares likely follow their own rhythm, driven by news about developments and approvals. The chart will show how independent its performance is from overall market fluctuations.
Market capitalization of the company, segment and market as a whole
IMDX - Market capitalization of the company Insight Molecular Diagnostics
Insight Molecular Diagnostics' stock price is a bet on the future of personalized medicine. This company's market cap reflects investors' faith in its diagnostic tests, which help doctors choose the right treatment based on a patient's genetic profile. Its dynamics are a barometer of progress in molecular diagnostics and its implementation in clinical practice.
IMDX - Share of the company's market capitalization Insight Molecular Diagnostics within the market segment - Medanalysis
Insight Molecular Diagnostics's market share in the medtech sector reflects its focus on advanced diagnostics. Its market share is likely driven by the development and commercialization of innovative tests, making it a small but potentially significant player in the future of personalized medicine.
Market capitalization of the market segment - Medanalysis
Insight Molecular Diagnostics is a medical analytics company. The chart below shows the overall market capitalization of the entire healthcare sector. Its dynamics reflect the growing role of precision diagnostics in modern personalized medicine.
Market capitalization of all companies included in a broad market index - GURU.Markets
Insight Molecular Diagnostics is a company developing and commercializing diagnostic tests. Its market capitalization reflects the potential of its molecular diagnostics technologies. The chart below shows the economic weight of the medical testing sector.
Book value capitalization of the company, segment and market as a whole
IMDX - Book value capitalization of the company Insight Molecular Diagnostics
Insight Molecular Diagnostics is an early-stage company. Its book value is primarily derived from cash raised for R&D. The chart below shows how this capital is spent on developing new diagnostic tests. This is a visualization of its financial "running headroom."
IMDX - Share of the company's book capitalization Insight Molecular Diagnostics within the market segment - Medanalysis
Insight Molecular Diagnostics develops diagnostic tests. Its core business is its cutting-edge laboratories. The asset share chart shows how the company invests in the unique and capital-intensive physical infrastructure that is the heart of its diagnostic technology.
Market segment balance sheet capitalization - Medanalysis
Insight Molecular Diagnostics is a diagnostics company. Its value lies in its unique tests, not its manufacturing facilities. Its tangible assets are its state-of-the-art laboratories. The graph will show whether this "lightweight," science-driven model is typical for the entire diagnostics sector.
Book value of all companies included in the broad market index - GURU.Markets
Insight Molecular Diagnostics' balance sheet represents capital invested in the development and commercialization of diagnostic tests for detecting genetic markers for cancer. The book value chart shows the resources focused on this cutting-edge area of personalized medicine.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Insight Molecular Diagnostics
Insight Molecular Diagnostics (probably imaware, privately held) specializes in at-home diagnostic tests. Its value lies not in its labs, but in its platform, brand, and consumer access. A publicly traded company would demonstrate how the market views the shift from traditional medicine to personalized tests that can be performed at home.
Market to book capitalization ratio in a market segment - Medanalysis
Insight Molecular Diagnostics (IMDX) is arguably a medical diagnostics company. Its value lies in its testing technologies, not its laboratories. The chart clearly demonstrates how the market valuation based on the potential of its tests can be a multiple of its book value.
Market to book capitalization ratio for the market as a whole
Insight Molecular Diagnostics (IMDX) is likely an early-stage biotech company. The chart for such companies shows how the market values a scientific idea. Market capitalization is not tied to tangible assets but rather represents investors' pure bet that the company's technology will successfully navigate all stages of research and reach the market.
Debts of the company, segment and market as a whole
IMDX - Company debts Insight Molecular Diagnostics
As a medical diagnostics company, Insight Molecular Diagnostics requires investment in research, development, and validation of new tests. Debt instruments can be a way to finance these processes until regulatory approval and commercialization, as demonstrated by the financial strategy in this chart.
Market segment debts - Medanalysis
Insight Molecular Diagnostics is a company specializing in molecular diagnostics. Developing and validating new diagnostic tests is a knowledge- and capital-intensive process. This chart, showing standards for the biotech sector, provides insight into the financial needs of such companies as they move from laboratory research to bringing a certified test to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Insight Molecular Diagnostics
As its name suggests, Insight Molecular Diagnostics operates in the field of medical diagnostics, which requires significant scientific development. Developing and validating new tests is an expensive process. This chart shows the role debt plays in funding these activities, directly reflecting the company's financial risks on the path to commercialization.
Market segment debt to market segment book capitalization - Medanalysis
Developing diagnostic tests based on molecular technologies, like Insight Molecular's, requires significant investment in research and development. This chart shows the overall debt burden in the healthcare sector. It allows one to assess how the company's financial model at an early stage compares to the average for the capital-intensive diagnostics industry.
Debt to book value of all companies in the market
Insight Molecular Diagnostics (if it's the correct company for the IMDX ticker) operates in the medical diagnostics industry. Developing new tests and equipment is capital-intensive. This chart helps assess how conservative their debt strategy for funding research and market entry is compared to the market as a whole.
P/E of the company, segment and market as a whole
P/E - Insight Molecular Diagnostics
This chart shows the valuation of Insight Molecular Diagnostics, a company operating in the field of molecular diagnostics. For a company in this sector, the valuation reflects investors' confidence in its technology platform and ability to develop and commercialize accurate and in-demand medical tests.
P/E of the market segment - Medanalysis
This indicator represents the average valuation for the molecular diagnostics sector, where Insight Molecular Diagnostics operates. It reflects the overall level of investor optimism regarding the development of personalized medicine. The chart provides a benchmark for understanding how the market values the company's technology platform.
P/E of the market as a whole
Insight Molecular Diagnostics is a molecular diagnostics company focused on developing tests that help detect diseases early and tailor treatments. This chart shows the current sentiment in the healthcare sector. It helps understand how the market views the company's diagnostic platform compared to other players in this rapidly developing field.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Insight Molecular Diagnostics
Insight Molecular Diagnostics is likely a company specializing in the development and provision of molecular diagnostics services for the detection and analysis of diseases at the genetic level. Its future depends on scientific development and the commercialization of tests. This timeline would reflect investor expectations regarding its technologies and their application in personalized medicine.
%20P%2FE%20Insight%20Molecular%20Diagnostics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Insight-Molecular-Diagnostics&v=1772567687904 "Chart of the company's future (projected) P/E Insight Molecular Diagnostics")
Future (projected) P/E of the market segment - Medanalysis
Insight Molecular Diagnostics is a young company working in the field of molecular diagnostics. Its goal is to develop new tests for detecting and monitoring diseases at the genetic level. The chart reflects expectations for the biotech sector, providing context for assessing how the market as a whole views the prospects and risks in this cutting-edge field of medicine.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Medanalysis&v=1772567687946 "Future (projected) P/E graph of the market segment - Medanalysis")
Future (projected) P/E of the market as a whole
Insight Molecular Diagnostics is a company specializing in the development of diagnostic tests. Their success depends on scientific innovation and the needs of the healthcare system. This graph of overall expectations shows the investor appetite for medicine. Market optimism facilitates funding for the development and commercialization of new, more accurate diagnostic methods.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772567687981 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Insight Molecular Diagnostics
Insight Molecular Diagnostics is a molecular diagnostics company. This chart reflects its financial performance as it moves toward commercialization of its diagnostic tests. Future profits depend on regulatory approvals, clinical implementation of the tests, and insurance reimbursement.
Profit of companies in the market segment - Medanalysis
BeLive Holdings is a technology company providing interactive streaming solutions. Its profitability depends on the growth of the live video market and its ability to monetize its services. This chart shows how demand for interactive content from media, retail, and corporations is creating new markets, but competition for technological leadership is fierce.
Overall market profit
Insight Molecular Diagnostics is an early-stage diagnostic testing company. Its potential success depends entirely on scientific development, clinical validation, and regulatory approval. It is an example of a business whose future value is created in the laboratory, not in the marketplace, whose overall dynamics are illustrated by this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Insight Molecular Diagnostics
Insight Molecular Diagnostics is likely an early-stage company specializing in molecular diagnostics. Revenue projections for such companies depend on the development, approval, and commercialization of their diagnostic tests. The chart would reflect analysts' speculative expectations regarding the company's technology platform and its potential in the medical testing market.
%20profit%20of%20the%20company%20Insight%20Molecular%20Diagnostics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Insight-Molecular-Diagnostics&v=1772567688184 "Graph of future (projected) profit of the company Insight Molecular Diagnostics")
Future (predicted) profit of companies in the market segment - Medanalysis
Insight Molecular Diagnostics, as its name suggests, is a molecular diagnostics company. These companies develop tests to detect diseases at the genetic level. This chart shows profitability forecasts for the medical analytics sector. It reflects the growing demand for personalized medicine and accurate diagnostics.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Medanalysis&v=1772567688264 "Graph of future (predicted) profits of companies in a market segment - Medanalysis")
Future (predicted) profit of the market as a whole
Insight Molecular Diagnostics focuses on developing tests for early cancer detection. This is an area where demand is driven by medical needs, not economics. However, the overall profit expectations shown in this chart influence public and private healthcare funding, as well as the investment climate for biotech companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772567688330 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Insight Molecular Diagnostics
Insight Molecular Diagnostics is a company specializing in the development and commercialization of diagnostic tests. At an early stage, it aims to carve out a niche in the molecular diagnostics market. Its minimum revenue estimate on this chart reflects investors' confidence in the potential of its technologies and the future demand for accurate and rapid testing methods.
P/S market segment - Medanalysis
Insight Molecular Diagnostics is a company specializing in the development and delivery of advanced molecular-based diagnostic tests. Its future revenue depends on the commercialization and clinical adoption of its tests. This chart reflects the average valuation in the sector, allowing one to assess the market's perception of Insight Molecular's potential.
P/S of the market as a whole
Insight Molecular Diagnostics, formerly known as OncoCyte, focuses on developing diagnostic tests for early-stage cancer detection. The company's valuation depends on the success of its diagnostic products. This chart, showing average valuations, clearly demonstrates the premium investors place on the company's revenue, which offers life-saving technologies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Insight Molecular Diagnostics
Insight Molecular Diagnostics is a company specializing in the development of diagnostic tests. This chart shows how investors assess the future commercial potential of its developments. The assessment is based on expectations for successful completion of research, regulatory approval, and the launch of new diagnostic products.
%20P%2FS%20Insight%20Molecular%20Diagnostics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Insight-Molecular-Diagnostics&v=1772567688719 "The graph of the company's future (projected) P/S Insight Molecular Diagnostics")
Future (projected) P/S of the market segment - Medanalysis
Insight Molecular Diagnostics develops and commercializes diagnostic tests that help detect diseases at the molecular level. The company's technologies are aimed at improving the accuracy and speed of diagnostics. This chart shows the market estimate of the company's future sales compared to other players in the molecular diagnostics sector.
%20P%2FS%20market%20segment%20graph%20-%20Medanalysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Medanalysis&v=1772567688749 "Future (projected) P/S market segment graph - Medanalysis")
Future (projected) P/S of the market as a whole
Future revenue expectations in medicine are linked to personalized treatment approaches. Insight Molecular Diagnostics, like many companies in this field, is developing diagnostic tests that help select the right treatment for each patient. The development of this area inspires confidence in a more effective and cost-effective future of medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772567688754 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Insight Molecular Diagnostics
Insight Molecular Diagnostics is an early-stage company focused on developing new diagnostic tests. Currently, it likely does not have significant commercial revenue. Its cash flow reflects the R&D phase, which is funded by investments rather than ongoing sales.
Sales of companies in the market segment - Medanalysis
Insight Molecular Diagnostics is a young company focused on developing cutting-edge molecular diagnostics. This chart shows total revenue in the medical analytics sector. It reflects a vast and growing market, in which new players like IMDX are seeking to carve out a niche with innovative approaches to early disease detection.
Overall market sales
Insight Molecular Diagnostics is a company specializing in the development and delivery of diagnostic tests. Its success depends on innovations in molecular diagnostics and their implementation in clinical practice. This overall economic situation impacts overall healthcare costs and the system's ability to fund new, more accurate testing methods.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Insight Molecular Diagnostics
Insight Molecular Diagnostics is an early-stage company focused on developing diagnostic tests. Its future depends entirely on success in R&D and regulatory approvals. The revenue forecast is currently highly speculative and reflects only the most distant expectations of analysts regarding future commercialization.
%20sales%20of%20the%20company%20Insight%20Molecular%20Diagnostics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Insight-Molecular-Diagnostics&v=1772567689186 "Schedule of future (projected) sales of the company Insight Molecular Diagnostics")
Future (projected) sales of companies in the market segment - Medanalysis
Insight Molecular Diagnostics is a company specializing in the development of diagnostic tests for disease detection and monitoring. Its success depends on the accuracy of its tests and their acceptance by the medical community. This chart shows projected sales for the entire medical analytics sector, reflecting analysts' expectations for the growth of the diagnostic solutions market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Medanalysis&v=1772567689217 "Schedule of future (projected) sales of companies in the market segment - Medanalysis")
Future (projected) sales of the market as a whole
Insight Molecular Diagnostics (IMDX) is a molecular diagnostics company. Its success depends on the development, approval, and commercialization of accurate and in-demand tests. This overall economic activity impacts healthcare system budgets, which determine the widespread adoption of new diagnostic methods in clinical practice.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772567689248 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Insight Molecular Diagnostics
Insight Molecular Diagnostics, as its name suggests, operates in the field of molecular diagnostics. This metric would reflect the company's progress from research to commercialization. It would demonstrate how successfully the company converts revenue from its diagnostic tests into net profit, covering R&D and approval costs.
Market segment marginality - Medanalysis
Insight Molecular Diagnostics is a medical diagnostics company. Its profitability depends on the development and commercialization of accurate and in-demand tests, as well as the efficiency of its laboratory processes. This chart allows you to evaluate the company's operating model in comparison to other players in the molecular diagnostics market.
Market marginality as a whole
Insight Molecular Diagnostics (formerly IMAC Holdings) is focused on the development and commercialization of advanced diagnostic tests. Their future depends on the success of their R&D and regulatory approvals. This overall profitability curve does not directly impact their research activities, but it may impact the overall investment climate in the medical diagnostics sector.
Employees in the company, segment and market as a whole
Number of employees in the company Insight Molecular Diagnostics
Insight Molecular Diagnostics is an early-stage company focused on developing new diagnostic tests. At this stage, a small but highly effective scientific team plays a key role. This graph shows the minimum team size typical for a startup focused on fundamental research and technology development.
Share of the company's employees Insight Molecular Diagnostics within the market segment - Medanalysis
Insight Molecular Diagnostics (formerly OncoCyte) focuses on developing tests for early cancer detection. This chart shows the percentage of scientists in the field of molecular oncology diagnostics that the company employs. Its team is working on developing non-invasive tests that can save lives through early detection.
Number of employees in the market segment - Medanalysis
Insight Molecular Diagnostics is a company specializing in the development and application of advanced molecular diagnostics methods. This chart shows overall employment in the medical analysis sector. Its growth reflects the shift in medicine toward personalized approaches, where accurate molecular diagnostics are becoming the key to effective treatment.
Number of employees in the market as a whole
Insight Molecular Diagnostics is a company specializing in the development and implementation of advanced molecular diagnostic methods. Accurate and rapid diagnostics are key to the effective treatment of many diseases. This employment chart also reflects the growth of the personalized medicine sector, which requires highly qualified laboratory technicians, geneticists, and bioinformaticians.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Insight Molecular Diagnostics (IMDX)
Insight Molecular Diagnostics is a company specializing in medical diagnostics. In this industry, the cost per employee is typically very high, as this chart should reflect. The market values not the number of tests, but the uniqueness and accuracy of the technology, patents, and scientific potential concentrated in a small team of highly qualified specialists.
%20of%20the%20company%20Insight%20Molecular%20Diagnostics%20(IMDX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Insight-Molecular-Diagnostics-IMDX&v=1772567689556 "Chart of market capitalization per employee (in thousands of dollars) of the company Insight Molecular Diagnostics (IMDX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Medanalysis
Insight Molecular Diagnostics, as its name suggests, operates in the field of molecular diagnostics. This is a field at the intersection of biotechnology and medicine, where test accuracy and scientific development play a key role. This metric demonstrates the value the market places on their technologies and intellectual property, relative to the team that creates and markets them.
%20by%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Medanalysis&v=1772567689585 "Market capitalization per employee (in thousands of dollars) by market segment - Medanalysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Insight Molecular Diagnostics, as its name suggests, is a medical diagnostics company. The value of such companies is determined by the accuracy and uniqueness of their tests, as well as their intellectual property. The per-employee valuation will be high, reflecting the research-intensive nature of the business, where a small team of scientists can create a breakthrough diagnostic product.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772567689610 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Insight Molecular Diagnostics (IMDX)
Insight Molecular Diagnostics is a biotech R&D company, apparently in its early stages. They are focused on developing new molecular diagnostics methods. This chart reflects their current status: it shows the net loss (research expenses) per scientist working on diagnostic tests.
%20Chart%20Insight%20Molecular%20Diagnostics%20(IMDX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Insight-Molecular-Diagnostics-IMDX&v=1772567689633 "Company Profit Per Employee (in thousands of dollars) Chart Insight Molecular Diagnostics (IMDX)")
Profit per employee (in thousands of dollars) in the market segment - Medanalysis
Insight Molecular Diagnostics is an early-stage company working in the field of molecular diagnostics. This metric is not key during the R&D phase. The graph represents a benchmark for commercially successful laboratories. IMDX's goal is to develop and validate tests that will enable them to achieve and exceed this industry benchmark in future performance.
%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Medanalysis&v=1772567689659 "Chart of profit per employee (in thousands of dollars) in the market segment - Medanalysis")
Profit per employee (in thousands of dollars) for the market as a whole
Insight Molecular Diagnostics (IMDX) is an early-stage diagnostic testing company. Business in this field requires significant investment in R&D and lengthy clinical validation. This graph will likely show a negative value, as each research employee is currently a cost center.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772567689717 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Insight Molecular Diagnostics (IMDX)
For Insight Molecular Diagnostics, a company specializing in molecular diagnostics, this graph reflects the commercialization of its tests. Increased revenue per employee will indicate the demand for its tests in clinical practice for accurate diagnosis and treatment selection.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Insight-Molecular-Diagnostics-IMDX&v=1772567689789 "Sales chart per company employee Insight Molecular Diagnostics (IMDX)")
Sales per employee in the market segment - Medanalysis
Insight Molecular Diagnostics (IMDX) is a company specializing in diagnostic testing development. It's a research-intensive business. This metric reflects the average revenue per employee for the segment. It helps assess how productive their R&D team is in commercializing their tests compared to other companies in the medical diagnostics sector.
Sales per employee for the market as a whole
Insight Molecular Diagnostics (IMDX) is a company developing diagnostic tests. Currently, the company has no commercial revenue, and its activities are purely R&D. This chart for IMDX shows zero values. Potential future growth would indicate successful licensing of their developments or approval of their tests.
Short shares by company, segment and market as a whole
Shares shorted by company Insight Molecular Diagnostics (IMDX)
Insight Molecular Diagnostics appears to be a speculative early-stage company in the medical diagnostics space. Such companies often lack revenue and burn through capital. This chart likely reflects the high investor skepticism regarding its technology, its ability to pass clinical trials, and the lack of a clear path to commercialization.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Insight-Molecular-Diagnostics-IMDX&v=1772567689930 "Short Shares Chart for the Company Insight Molecular Diagnostics (IMDX)")
Shares shorted by market segment - Medanalysis
Insight Molecular Diagnostics (IMDX) is a company focused on molecular diagnostics. This chart reflects the aggregate short position in the medical diagnostics sector. It shows the overall level of investor uncertainty about the ability of small companies to commercialize new tests or the level of reimbursement from insurers.
Shares shorted by the overall market
Insight Molecular (IMDX) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing IMDX will be unable to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Insight Molecular Diagnostics (IMDX)
Insight Molecular Diagnostics (IMDX) is a company operating in the medical diagnostics sector. For such speculative R&D-stage stocks, this chart is a gauge of pure hype. It shows when investor euphoria (overbought) or sharp disappointment (oversold) reaches extreme levels.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Insight-Molecular-Diagnostics-IMDX&v=1772567690176 "RSI 14 indicator chart for the company's stock Insight Molecular Diagnostics (IMDX)")
RSI 14 Market Segment - Medanalysis
Insight Molecular (IMDX) — *diagnostics* (biotech). The "Medanalysis" (diagnostics) sector thrives on R&D. RSI_14_Seg shows the "temperature" of the *entire* industry. It helps us understand: is IMDX's growth a "niche" or a general "overheating" (or "overselling")?
RSI 14 for the overall market
Insight Molecular (IMDX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IMDX (Insight Molecular Diagnostics)
Insight Molecular Diagnostics (IMDX) is a company specializing in the development of diagnostic tests for the early detection of cancer and other diseases. This chart shows the speculative average price target from analysts, based on their assessment of the company's R&D portfolio and commercialization potential.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IMDX-Insight-Molecular-Diagnostics&v=1772567690285 "A chart showing analyst consensus forecasts for the expected stock price. IMDX (Insight Molecular Diagnostics)")
The difference between the consensus estimate and the actual stock price IMDX (Insight Molecular Diagnostics)
Insight Molecular Diagnostics (IMDX) is a company focused on developing and commercializing advanced diagnostic tests. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their confidence in the company's scientific platform and its ability to bring tests to market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IMDX-Insight-Molecular-Diagnostics&v=1772567690359 "A chart showing the difference between the consensus forecast and the actual stock price. IMDX (Insight Molecular Diagnostics)")
Analyst consensus forecast for stock prices by market segment - Medanalysis
Insight Molecular (IMDX) is a company specializing in molecular diagnostics, specifically developing tests for the early detection and monitoring of cancer. This chart shows analysts' overall expectations for the entire medical testing sector. It reflects whether experts believe the liquid biopsy and early diagnostics market will grow.
Analysts' consensus forecast for the overall market share price
Insight Molecular Diagnostics (IMDX) is a company specializing in the development of diagnostic tests that help detect diseases at the molecular level. This chart shows the overall risk appetite. For IMDX, which operates in the defensive yet innovative healthcare sector, overall market optimism is important for attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Insight Molecular Diagnostics
Insight Molecular (IMDX) appears to be a company operating in the hot field of molecular diagnostics. They are likely developing advanced tests (possibly DNA/RNA-based) for the early detection of diseases (cancer, infections). This chart is likely a speculative R&D bet. Its valuation reflects the market's faith in their scientific platform and their potential for precision medicine.
AKIMA Market Segment Index - Medanalysis
Insight Molecular Diagnostics (IMDX) is a company operating in the molecular medical diagnostics sector. (Note: The ticker symbol IMDX is little known.) This chart shows the average index for the medical diagnostics sector. It allows investors to assess how IMDX performs compared to its peers.
The AKIM Index for the overall market
Insight Molecular is a company working in molecular diagnostics and genomic analysis (information is limited, likely microcapsule). This chart, reflecting the market average, is a backdrop. It helps assess how this niche healthcare market, dependent on the introduction of new tests, compares to overall macroeconomic trends.
